High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
After ripping through the first half of the year, memory stocks are struggling to regain momentum as growing concerns about the state of the artificial intelligence trade overshadow their strong fundamental backdrop.
SELLAS Life Sciences Group (SLS) is drawing fresh attention as investors reassess immune based cancer therapy stocks following Moderna and Merck’s Phase 3 cancer vaccine update and the broader oncology rally it helped spark. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of $13.40, SELLAS Life Sciences Group has seen a 72.24% 90 day share price return and a very large 1 year total shareholder return. This suggests momentum has been building as attention shifts...
Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.
Moderna (MRNA) is back in focus after reporting that its personalized mRNA cancer therapy intismeran achieved primary and key secondary goals in a large Phase 3 melanoma trial, outperforming standard immunotherapy alone. See our latest analysis for Moderna. Following the trial update, Moderna’s recent share price moves have been sharp, with a 7 day share price return of 109.44% and a year to date share price return of 331.98%, while the 1 year total shareholder return is 408.43%. This...
The Nasdaq Composite fell 1%. The bond market was a major reason stocks took a tumble. Treasury yields rose on Thursday, with the 30-year Treasury bond reaching 5.25% and the 10-year reaching 4.7% (bond prices and yields move inverse to each other).
Breaking news: Moderna isn't just a "pandemic stock" after all.
Find insight on Moderna, Merck KGaA, Novonesis and more in the latest Market Talks covering the health care sector.
The Nasdaq closed below its Aug. 4 follow-through day low, a highly bearish signal for the market rally. Walmart, SpaceX, CrowdStrike were big losers.
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the stock surged over 175% in the previous session on positive clinical trial news.
Historic momentum is colliding with increasingly stretched technical conditions
One breakthrough could reshape the post-Keytruda earnings story
Moderna stock has delivered an exceptionally strong run over the past year, yet the valuation checks currently lean expensive and raise questions about how much optimism is already priced in. Moderna has returned very roughly 5.5x over the past 12 months, which sets a high bar for any further upside to be justified by fundamentals. Positive late stage melanoma vaccine data with Merck can support higher growth expectations for Moderna. The risk is that clinical, regulatory or execution...
Michael Reinking, Senior Market Strategist at the NYSE, recaps a week dominated by Treasury Secretary Bessent, whose doubled liquidity support buybacks reignited the debasement trade, sending gold back above 4,500 and triggering a massive crypto short squeeze that propelled Bitcoin up ~15% and Ethereum up 25%. Escalating Iran tensions pushed ICE Brent into the low 90s after a 60-day ceasefire expired, while equity markets drifted lower with the S&P 500 down ~1.5% as retail earnings disappointed broadly and healthcare surged nearly 4% on landmark cancer trial results from Merck and Moderna. Looking ahead, next week's PCE print, Nvidia earnings, and Fed Chair Warsh's first Jackson Hole speech are the marquee events to watch.
<p>Moderna's 177% pop on a Phase 3 cancer-vaccine win rippled far beyond one stock.</p>
Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index decreasing 0.9% a
Moderna was the best performing stock in the S&P 500 yesterday. Moderna stock had fallen over 22% on Thursday in its worst single-day decline on record, according to Dow Jones Market Data. The stock more than doubled in the trading session prior.
Profit-taking followed a record-setting rally sparked by the first successful Phase 3 trial of an mRNA cancer treatment.
The trial met both endpoints in the readout, removing the inconclusive outcome management itself had flagged, and short sellers in the stock took a record single-session loss.
The rally around MRNA names began on Wednesday after Merck and Moderna reported positive late-stage results for their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.
Moderna stock surged following positive cancer-vaccine data, burning short sellers and spilling over into the semi sector.
BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI to $80 from $70 and kept a Buy rating.
A new mRNA cancer vaccine hit its goal in melanoma patients, giving a healthcare giant a fresh growth story.
Moderna stock soared 177% after a major cancer vaccine breakthrough. See Wall Street’s latest MRNA price targets and whether the rally can continue.
Moderna Inc (NASDAQ:MRNA, XETRA:0QF)'s melanoma trial success is prompting Wall Street to assign new platform value to the company's oncology pipeline, Jefferies said, as investors look beyond its COVID-dependent revenue base. The Jefferies note said intismeran vipatamotide (mRNA-4157), an...
Moderna and Merck scored a big win for their cancer vaccine on Wednesday. But analysts say it's too early to call it a home run.
Moderna's mRNA cancer vaccine sent shares on one of biotech's wildest two-day rides in years, but the brutal Thursday reversal raises a question investors now have to answer: does the science justify what the market priced in?
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
